Interesting to reread that press release. The highlights I get from this are the following:
1)The results obtained with the assay format used in several automated instruments including the Abbott ArchitectTM. 68 breast, gastric and other types of cancers were compared to 52 normal patients and the AUC scoring obtained was 0.954 (a perfect discrimination between cancer and normal samples has a score of 1.0). Similar results were independently obtained in Abbott’s facility for prostate cancer samples.
TOTAL 120 samples. Anyone venture a guess as to how many samples are required for the 510K?
2)The second study was done in collaboration with Abbott and the University of Munich to determine the best type of specimen collecting tube for RECAF testing in a clinical laboratory environment which appears to have been completed.
The key elements are that this is independent of Biocurex, done in a clinical laboratory environment BY ABBOTT WITH THE UNIVERSITY OF MUNICH. It is required by the FDA to show that the test could perform in a clinical setting.
Dr Moro just returned from Munich. Coincidence? I think not.
Quote..."We are getting closer and closer to the commercialization of a cancer test that has the potential to be used for screening patients in much the same way a blood sugar or cholesterol reading is requested as part of a routine blood test."
IMO, we are setting up for some good news shortly. Dr Moro has created this beautiful diamond and now he is just polishing it up for the rest of the world to see. He must make sure that it is as close to flawless, because there are no second chances.
Thanks GG, it is definitely worth a second look.
I remember we pieced together the ISOBM before it was announced and the pieces of the puzzle are starting to come together once again setting us up for some great things in our future.
